Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects
Angrist, B.; Gershon, S.
Advances in Biochemical Psychopharmacology 16: 677-680
1977
ISSN/ISBN: 0065-2229 PMID: 883566 Document Number: 117223
Document emailed within 1 workday
Related Documents
Breese, G.R.; Baumeister, A.A.; McCown, T.J.; Emerick, S.G.; Frye, G.D.; Crotty, K.; Mueller, R.A. 1984: Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine Journal of Pharmacology and Experimental Therapeutics 231(2): 343-354Langer, G.; Sachar, E.J.; Gruen, P.H. 1978: Prolactin response to neuroleptic drugs in normal and schizophrenic subjects Psychopharmacology Bulletin 14(1): 8-9
Tadori, Y.; Kobayashi, H. 2014: The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors Nihon Shinkei Seishin Yakurigaku Zasshi 34(5-6): 127-132
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z. 1980: Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
Hoffmann, I.S.; Talmaciu, R.K.; Cubeddu, L.X. 1986: Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release Journal of Pharmacology and Experimental Therapeutics 238(2): 437-446
Gottschalk, L.A. 1978: A preliminary approach to the problems of relating the pharmacokinetics of phenothiazines to clinical response with schizophrenic patients Psychopharmacology Bulletin 14(3): 35-39
Pirtosek, Z.; Flisar, D. 2004: Neuroprotection and dopamine agonists Advances in Experimental Medicine and Biology 541: 55-74
Heins, J.R. 1997: New dopamine agonists on the horizon South Dakota Journal of Medicine 50(7): 239-240
Zarifian, E. 1979: Dopa and dopamine agonists in depression L'Encephale 5(5 Suppl): 665-670
Teräväinen, H.; Calne, S.; Burton, K.; Beckman, J.; Calne, D.B. 1988: Efficacy of dopamine agonists in dystonia Advances in Neurology 50: 571-578
Kohli, J.D. 1990: Dopamine receptor agonists and antagonists Proceedings of the Western Pharmacology Society 33: 21-27
Girbes, A.R.; van Veldhuisen, D.J.; Smit, A.J. 1991: Dopamine agonists, a new perspective in cardiovascular therapy? Netherlands Journal of Medicine 39(1-2): 65-71
Gekht, A.B. 2002: Use of dopamine agonists in the treatment of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
van Harten, P.N.; Loonen, A.J.M. 2006: The restless legs syndrome can be treated with dopamine agonists Nederlands Tijdschrift Voor Geneeskunde 150(52): 2894; Author Reply 2894-5
Rack, M.J.; Baran, A.Sinan.; Richert, A.C.; Roffwarg, H.P. 2004: Cardiopulmonary complications of ergot-derivative dopamine agonists Journal of Clinical Psychiatry 65(10): 1429-30; Author Reply 1430
Aramideh, M.; de Weerd, A.W. 2006: The restless legs syndrome can be treated with dopamine agonists Nederlands Tijdschrift Voor Geneeskunde 150(40): 2173-2177
Ary, M.; Lomax, P.; Cox, B. 1977: Sensitivity to dopamine agonists in morphine dependent rats Proceedings of the Western Pharmacology Society 20: 375-380
Lertxundi, U.; Domingo-Echaburu, S.; Peral, J.; García, M. 2011: Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe? Psychopharmacology Bulletin 44(3): 66-68
Woolverton, W.L.; Goldberg, L.I.; Ginos, J.Z. 1984: Intravenous self-administration of dopamine receptor agonists by rhesus monkeys Journal of Pharmacology and Experimental Therapeutics 230(3): 678-683
McClelland, D.L.; Nakamoto, B.K.; Rosenkranz, R.P. 1987: Cardiovascular effects of centrally administered dopamine agonists and clonidine in the rat Proceedings of the Western Pharmacology Society 30: 243-247